NasdaqGS:ILMNLife Sciences
A Look At Illumina (ILMN) Valuation After Profitability Gains And SomaLogic Acquisition Guidance
Why Illumina’s latest quarter has put the stock back in focus
Illumina (ILMN) has drawn investor attention after reporting fourth quarter and full year 2025 results that showed stronger profitability, 20% growth in clinical consumables outside China, and fresh guidance that incorporates the SomaLogic acquisition.
See our latest analysis for Illumina.
The recent 1 day share price return of 2.07% to US$116.81 comes after earnings, new 2026 guidance and an ongoing buyback program that has...